Drugs & Therapy Perspectives

, Volume 21, Issue 1, pp 1–4 | Cite as

Letrozole is an effective option in the treatment of early-stage or advanced breast cancer in postmenopausal women

Drugs and Profile Reports
  • 24 Downloads

References

  1. 1.
    Beslija S, Bonneterre J, Burstein HJ, et al. Consensus on medical treatment of metastatic breast cancer. Breast Cancer Res Treat 2003; 81 Suppl. 1: S1–7CrossRefGoogle Scholar
  2. 2.
    Simon MS, Ibrahim D, Newman L, et al. Efficacy and economics of hormonal therapies for advanced breast cancer. Drugs Aging 2002; 19(6): 453–63PubMedCrossRefGoogle Scholar
  3. 3.
    Come SE, Buzdar AU, Arteaga CL, et al. Second international conference on recent advances and future directions in endocrine manipulation of breast cancer: summary consensus statement. Clin Cancer Res 2003 Jan; 9 Suppl. : 443s–6sPubMedGoogle Scholar
  4. 4.
    Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 2004; 64(11): 1213–30PubMedCrossRefGoogle Scholar
  5. 5.
    Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003 Nov 6; 349(19): 1793–802PubMedCrossRefGoogle Scholar
  6. 6.
    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001 Nov; 12(11): 1527–32PubMedCrossRefGoogle Scholar
  7. 7.
    Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003 Jun 1; 21(11): 2101–9PubMedCrossRefGoogle Scholar
  8. 8.
    Mouridsen H, Sun Y, Gershanovich M, et al. Significantly longer time to progression for Femara (letrozole) in patients with or without prior adjuvant tamoxifen: updated analysis of the double-blind, randomized, multinational phase III trial of letrozole compared to tamoxifen as first-line hormonal therapy for advanced breast cancer [abstract no. 256]. 25th Annual San Antonio Breast Cancer Symposium; 2002 Dec 11–14; San AntonioGoogle Scholar
  9. 9.
    Smith IE. Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy. J Steroid Biochem Mol Biol 2003 Sep; 86(3-5): 289–93PubMedCrossRefGoogle Scholar
  10. 10.
    Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001 M 15; 19(14): 3357–66PubMedGoogle Scholar
  11. 11.
    Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453–61PubMedGoogle Scholar
  12. 12.
    Rose C, Vtoraya O, Pluzanska A, et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003 Nov; 39(16): 2318–27PubMedCrossRefGoogle Scholar
  13. 13.
    Novartis Oncology. About Femara: European summary of product characteristics [online]. Available from URL: http://www.femara.com [Accessed 2004 Sep 2]
  14. 14.
    Novartis Oncology. Femara prescribing information [online]. Available from URL: http://www.us.femara.com [Accessed 2004 Sep 2]

Copyright information

© Adis Data Information BV 2005

Personalised recommendations